Biomarkers of prolonged time to treatment failure in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A real life patients-based nomogram and web app.

Maysa Tamara Silveira Vilbert,Natasha Carvalho Pandolfi,Marcelle Goldner Cesca,Vinícius Fernando Calsavara,Marcelo Corassa,José Augusto Rinck,Aldo A. Dettino,Ricardo Lima Coelho,Mariana Pinheiro Xerfan,Thiago Bueno Oliveira

Biomarkers of prolonged time to treatment failure in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A real life patients-based nomogram and web app.

2020

Maysa Tamara Silveira Vilbert
Natasha Carvalho Pandolfi
Marcelle Goldner Cesca
Vinícius Fernando Calsavara
Marcelo Corassa
José Augusto Rinck
Aldo A. Dettino
Ricardo Lima Coelho
Mariana Pinheiro Xerfan
Thiago Bueno Oliveira

202Background: Survival outcomes for metastatic castration resistant prostate cancer (mCRPC) patients (pts) have greatly improved following the approval of Docetaxel and abiraterone(Abi)/enzalutami...

Keywords:

Oncology
Biomarker (medicine)
Prostate cancer
Castration
Abiraterone
Pathology
treatment failure
Nomogram
Internal medicine
Medicine
Enzalutamide
castration resistant
Docetaxel
time to treatment failure

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations